Request Demo
Last update 08 Mar 2025
Andarix Pharmaceuticals, Inc.
Last update 08 Mar 2025
Overview
Basic Info
Introduction Andarix Pharmaceuticals is focused on creating innovative cancer therapies that are tailored to the specific needs of individual patients. Their treatments are designed to target specific cancers at the molecular level, and they use companion diagnostics to identify patients with the appropriate molecular signature who are most likely to benefit from these therapies. The company's products are based on a proprietary peptide targeted radionuclide technology that allows for both imaging and targeted radiotherapy of cancer cells. With a team of experienced professionals, Andarix is dedicated to developing treatments that will significantly improve outcomes for cancer patients. |
Tags
Digestive System Disorders
Neoplasms
Endocrinology and Metabolic Disease
Peptide Conjugate Radionuclide
Therapeutic radiopharmaceuticals
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
NCT00100256
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
100 Clinical Results associated with Andarix Pharmaceuticals, Inc.
Login to view more data
Login to view more data
01 Dec 2014Journal of nuclear medicine : official publication, Society of Nuclear MedicineQ1 · MEDICINE
The Somatostatin Analog 188Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts
Q1 · MEDICINE
Article
Author: Adams, Christopher T ; Azure, Michael T ; Nelson, Carol A ; Zinn, Kurt R
METHODS:
(188)Re-P2045 was intravenously administered every 3 d for 16 d to nude mice with AR42J tumor xenografts that were approximately 20 mm(3) at study initiation. Tumor volumes were recorded throughout the dosing period. At necropsy, all tissues were assessed for levels of radioactivity and evaluated for histologic abnormalities. Clinical chemistry and hematology parameters were determined from terminal blood samples. The affinity of nonradioactive (185/187)Re-P2045 for somatostatin receptors was compared in human NCI-H69 and rat AR42J tumor cell membranes expressing predominantly SSTR2.
RESULTS:
In the 1.85- and 5.55-MBq groups, tumor growth was inhibited in a dose-dependent fashion. In the 11.1-MBq group, tumor growth was completely inhibited throughout the dosing period and for 12 d after the last administered dose. The radioactivity level in tumors 4 h after injection was 10 percentage injected dose per gram, which was 2-fold higher than in the kidneys. (188)Re-P2045 was well tolerated in all dose groups, with no adverse clinical, histologic, or hematologic findings. The nonradioactive (185/187)Re-P2045 bound more avidly (0.2 nM) to SSTR2 in human than rat tumor membranes, suggesting that these studies are relevant to human studies.
CONCLUSION:
(188)Re-P2045 is a promising therapeutic candidate for patients with somatostatin receptor-positive cancer.
100 Deals associated with Andarix Pharmaceuticals, Inc.
Login to view more data
100 Translational Medicine associated with Andarix Pharmaceuticals, Inc.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 12 Mar 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free